Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Pathology|March 30, 2016
Molecular subtyping of diffuse large B-cell lymphoma: update on biology, diagnosis and emerging platforms for practising pathologistsGrace K Gifford, Anthony J Gill, William S Stevenson
Clinical Transplantation|January 22, 2005
Nephrotic syndrome after stem cell transplantationWilliam S Stevenson, Brian J Nankivell, Mark S Hertzberg
Leukemia & Lymphoma|March 26, 2015
The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabineKyle Crassini, William S Stevenson, Stephen P Mulligan, et al.
British Journal of Haematology|August 1, 2019
Molecular pathogenesis of chronic lymphocytic leukaemiaKyle Crassini, William S Stevenson, Stephen P Mulligan, et al.
Platelets|May 19, 2022
Prevalence and natural history of variants in the ANKRD26 gene: a short review and update of reported casesHrushikesh Vyas, Ahmad Alcheikh, Gillian Lowe, et al.
Molecular Cytogenetics|December 18, 2013
Polyploidy in myelofibrosis: analysis by cytogenetic and SNP array indicates association with advancing diseaseNisha R Singh, Christine M Morris, Mary Koleth, et al.
The Medical Journal of Australia|October 31, 2018
Preventing ovarian failure associated with chemotherapyWanyuan Cui, Catharyn Stern, Martha Hickey, et al.
British Journal of Haematology|May 17, 2018
MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironmentKyle Crassini, Yandong Shen, William S Stevenson, et al.
Leukemia & Lymphoma|June 19, 2018
Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cellsKyle Crassini, Tahni Pyke, Yandong Shen, et al.
Research and Practice in Thrombosis and Haemostasis|January 29, 2020
The clinical heterogeneity of RUNX1 associated familial platelet disorder with predisposition to myeloid malignancy - A case series and review of the literatureCatherine Tang, David J Rabbolini, Marie-Christine Morel-Kopp, et al.
Pageof 3